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A b s t r a c t
Introduction: Although surgical endarterectomy remains the treatment of choice for carotid artery stenosis, stenting plays an 
important role as an alternative treatment modality, especially in high-risk patients. The actual safety profile associated with stent-
ing procedures is probably better than that reported by randomized controlled trials.
Aim: To assess the safety of stent implantations in extracranial arteries supplying the brain, and also to identify risk factors 
associated with this procedure.
Material and methods: This was a post hoc analysis, with 30-day follow-up. We analyzed the results of treatment of 372 pa-
tients who underwent 408 procedures, 197 such procedures in asymptomatic, and 211 in symptomatic individuals. Stenting proce-
dures were performed using a technique and armamentarium which were tailored to the type and anatomy of lesions.
Results: There were 6 (1.5%) strokes, including 2 (0.5%) major strokes, 1 ipsi- and 1 contralateral, and 4 (1.0%) minor strokes. 
In asymptomatic patients there was 1 (0.3%) minor stroke. Transient ischemic attacks occurred in 5 (1.2%) patients. There were 
2 (0.5%) non-STEMI myocardial infarctions and 2 (0.5%) non-stroke related fatalities. Risk factors of these adverse events were di-
abetes mellitus, lesions localized in a tortuous segment of the artery, embolic material in the filter and bilateral stenoses of carotid 
arteries. Additional risk factors in asymptomatic patients were renal impairment and advanced coronary artery disease; and in 
symptomatic patients, grade 3 arterial hypertension, dislipidemia, cigarette smoking and lesions requiring predilatation.
Conclusions: Stenting procedures of extracranial arteries supplying the brain, which are tailored to the type and anatomy of 
lesions, seem to be relatively safe.
Key words: carotid artery stenting, proximal protection system, distal protection system.
Introduction
Although surgical endarterectomy remains the 
treatment of choice for the management of carotid ar-
tery stenosis [1–4], carotid artery stenting (CAS) plays 
an important role as an alternative treatment modality 
in patients with high risk associated with open sur-
gical treatment, and also those patients who present 
with carotid lesions of non-atherosclerotic etiology. Re-
ports published by experienced centers demonstrated 
a high efficacy of this procedure and low complication 
rates [5–9]. On the other hand, randomized controlled 
trials that compared surgical endarterectomy with 
CAS revealed better results of open surgical repair, 
with higher complication rates in the CAS arm [9, 10]. 
Thus, the actual safety profile associated with CAS and 
stenting procedures in other extracranial arteries sup-
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plying the brain is probably better than that reported 
by randomized controlled trials and potentially may be 
at least non-inferior to open surgical repair of these 
blood vessels.
Aim
This post hoc analysis, with 30-day follow-up, aimed 
to assess the safety and efficacy of stent implantation for 
the treatment of atherosclerotic lesions in the extracra-
nial arteries supplying the brain, and also to identify risk 
factors associated with this procedure.
Material and methods
We analyzed the results of treatment of 372 consecu-
tive patients (134 women and 238 men) who were man-
aged by our team at departments of vascular surgery 
from March 2011 to December 2015. Patients were aged 
69 ±8.3 years, and 20 (5.4%) patients were aged more 
than 80 years. A  total of 408 endovascular treatments 
with stent implantation have been performed, 197 such 
procedures in asymptomatic patients (group A), and 211 
stenting procedures in symptomatic patients (group B). 
Some patients underwent endovascular treatment more 
than once. Demographic and clinical characteristics of 
patients, including potential risk factors, are presented 
in Table I, and a comparison between asymptomatic and 
symptomatic patients regarding these risk factors is pro-
vided in Table II. 
Inclusion criteria for endovascular angioplasty with 
stent implantation comprised: more than 65% stenosis of 
the internal carotid artery (ICA) in symptomatic patients, 
more than 80% stenosis of the internal carotid artery in 
asymptomatic patients, and more than 90% stenosis of 
the vertebral, subclavian or proximal common carotid ar-
tery. Exclusion criteria for a stenting procedure comprised: 
highly calcified lesions, no adequate vascular access, con-
traindications for antiplatelet therapy and a  lack of pa-
tient’s consent. Symptomatic patients were managed at 
least 5 days after the neurologic event, preferentially on 
the 7th–10th day, depending on the findings of magnetic 
resonance imaging (MRI) of the brain and appearance of 
cerebral lesions revealed by this test; this was in line with 
recommendations from published studies [5, 8, 9].
The majority of stent implantations (367 procedures; 
90.0%) were performed for the treatment of lesions in 
the ICAs: 167 procedures in the right ICA (including one 
procedure with simultaneous treatment of coexisting 
tandem stenosis of the common carotid artery) and 200 
stenting procedures of the left ICA. Other treatments 
were performed to address lesions in the brachiocephal-
ic, subclavian and vertebral arteries; details are given in 
Table III. 
Standard preprocedural management of patients 
comprised multidisciplinary assessment, including neu-
rological, vascular and cardiologic consultations. Neuro-
logical assessment was performed at least before the 
procedure and on the first postprocedural day. Endovas-
cular procedures were performed by well-trained inter-
ventionalists, with an expertise of over 1000 endovascu-
lar procedures already carried out. 
Stent implantations were performed using the tech-
nique and armamentarium which were tailored to the 
type and anatomy of the lesion. The decision tree for 
such a choice included:
•	 anatomy of the arteries (type of the aortic arch, tor-
tuousness of the carotid arteries, patency of these 
arteries);
Table I. Demographic and clinical characteristics 
of patients; number of patients: N = 372, number 
of procedures: N = 408
Patients’ characteristics N %
Mean age ± SD 69 ±8.3
Patients older than 80 years 20 5
Male/female ratio 238/134 63/37
Asymptomatic patients 179 48
Risk factors N %
Stable coronary heart disease 139 37
Arterial hypertension 328 88
Diabetes mellitus type 2 112 30
Dislipidemia 226 61
Cigarette smoking 105 28
Renal impairment 31 9
Peripheral artery disease 50 13
History of percutaneous coronary 
angioplasty 
50 13
History of coronary artery bypass graft 
surgery
32 9
History of cancer 4 1
History of myocardial infarction 92 25
Symptomatic carotid artery stenosis 193 52
History of transient ischemic attack 107 29
History of stroke 86 23
Bilateral stenosis of the internal carotid 
artery
134 36
Occlusion of the internal carotid artery 51 14
Bilateral occlusion of the internal or 
common carotid arteries
3 0.8
Occlusion or stenosis of the subclavian 
artery
34 9
Stenosis of the vertebral artery 52 14
Occlusion of the brachiocephalic trunk 2 0.5
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•	 characteristics of the lesion (stable/unstable, pres-
ence of calcifications, sonographic features, such as 
homo- or hyperechogenicity, presence of thrombus);
•	 coexistence of lesions in other arteries: carotid, verte-
bral, subclavian, brachiocephalic trunk or intracranial 
arteries;
•	 choice of vascular access: femoral, radial or brachial.
Taking into account all four above-mentioned com-
ponents, firstly the proper vascular access was chosen, 
usually a femoral or radial, rarely a brachial one. Then, the 
protection system was selected, either a proximal or distal 
one. In the case of a distal protection system, also the type 
and length of the filter, as well as the type and size of the 
introducer sheath, were chosen. Depending on the charac-
teristics of the lesion, the design of the stent was selected: 
close-cell or open-cell, self-expandable or balloon-expand-
able. Finally, the size of the balloon dedicated for postdila-
tation of the stent was chosen. The endovascular proce-
dure was considered to be successful if either the lesion 
was fully expanded or residual stenosis was less than 20%.
Although a proximal protection system was the pre-
ferred one, in many patients it was necessary to use 
a  distal system, primarily due to coexisting significant 
lesions in other arteries supplying the brain. For exam-
ple, 106 (28.5%) patients presented with bilateral ste-
noses of the ICAs, and 51 (13.7%) other patients had at 
least one significant lesion in the vertebral or subclavian 
artery. Therefore, in the majority of cases we decided 
to apply a  distal protection system: in asymptomatic 
Table II. Risks factors in asymptomatic vs. symptomatic patients
Risk factor Asymptomatic patients 
(197 procedures)
Symptomatic patients 
 (211 procedures)
P-value
Mean age (± SD) 68.5 ±7.2 69.1 ±9.14 NS
Patients aged > 80 years 5 14 NS
Patients aged < 60 years 18 18 NS
Male patients 117 121 NS
Stable coronary heart disease 75 64 < 0.05
Congestive heart failure 5 11 NS
Cigarette smoking 49 56 < 0.05
Diabetes mellitus type 2 51 61 < 0.05
Arterial hypertension 155 173 < 0.05
Dislipidemia 112 118 NS
Renal impairment 12 19 NS
Peripheral arterial disease 23 27 NS
History of myocardial infarction 48 44 NS
History of percutaneous coronary angioplasty 20 31 < 0.05
History of coronary artery bypass graft surgery 18 15 NS
Aortic or mitral valve disease 2 0 NS
Contralateral stenosis of the internal carotid artery 45 61 0.06
Occlusion of the internal carotid artery 15 36 < 0.05
Occlusion of the subclavian artery 2 8 NS
Stenosis of the vertebral artery 10 24 < 0.05
NS – difference statistically not significant.
Table III. Location of the lesions treated (N = 408)
Artery N %
Left internal carotid artery 200 49
Right internal carotid artery 167 41
Brachiocephalic trunk 5 1.2
Right subclavian artery 2 0.5
Left subclavian artery 12 3
Left vertebral artery  
(including 4 intracranial lesions)
11 3
Right vertebral artery 5 1.1
Right common carotid artery 1 0.2
Left carotid common artery 5 1
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patients such a system was used in 140 (71.1%) cases 
and in symptomatic patients in 154 (73.0%) cases, while 
a  proximal protection system was used in 40 (20.3%) 
asymptomatic and 57 (27.0%) symptomatic patients. In 
a few patients presenting with stenoses of the subclavi-
an artery there was no need for the use of a protection 
system. On the other hand, in 2 symptomatic patients 
we applied both proximal and distal protection systems. 
Details regarding protection systems used are given in 
Table IV.
In 4 patients, due to symptomatic stenoses of the 
vertebral arteries, it was necessary to perform an intra-
cranial endovascular angioplasty. In 2 such cases it was 
also necessary to implant a stent: a balloon-expandable 
drug-eluting stent in 1 patient and a Wingspan stent – 
a self-expanding stent dedicated for intracranial lesions 
Table IV. Characteristics of protection systems and stents utilized in 408 procedures (375 CAS and 33 other 
procedures) in asymptomatic vs. symptomatic 
Variable Asymptomatic patients 
(197 procedures)
Symptomatic patients 
(211 procedures)
P-value
Proximal protection systems: 40 57 0.05
Mo.Ma (Medtronic, Minneapolis, MN, USA) 36 50 0.05
Gore Flow Reversal System (Gore & Associates, Inc., Flagstaff,  AZ, USA) 4 7 NS
Distal protection systems: 140 138 NS
SpiderFX (Covidien, ev3 Endovascular, Inc., Plymouth, MN, USA) 42 49 NS
Emboshield NAV6 (Abbott Vascular, Abbott Park, IL, USA) 37 44 NS
FilterWire EZ (Boston Scientific, Natick, MA, USA) 28 27 NS
RX Accunet (Abbott Vascular, Abbott Park, IL, USA) 23 15 NS
FiberNet (Medtronic, Minneapolis, MN, USA) 6 0 NS
Angioguard (Cordis, Fremont, CA, USA) 2 1 NS
Defender (Medtronic, Minneapolis, MN, USA) 2 2 NS
Stents:
Precise (Cordis, Fremont, CA, USA) 38 48 0.05
Carotid Wallstent (Boston Scientific, Natick, MA, USA) 47 54 0.05
Xact (Abbott Vascular, Abbott Park, IL, USA) 25 25 NS
Acculink (Abbott Vascular, Abbott Park, IL, USA) 39 28 0.05
Cristallo Ideale (Medtronic, Minneapolis, MN, USA) 31 36 NS
Roadsaver (Terumo, Tokyo, Japan) 1 0 NS
Balloon-expandable stents 15 11 NS
Drug-eluting stents 1 9 0.05
Close-cell design stents 104 115 NS
Open-cell stents 93 96 NS
Vascular access:
Femoral 193 205 NS
Radial 2 5 NS
Brachial 2 1 NS
Macroscopically visible embolic material in protection system:
Single plaque or thrombus 15 28 0.05
A little debris 2 8 NS
A lot of debris 3 4 NS
NS – difference statistically not significant.
Paweł Latacz et al. Endovascular treatment of occluded extracranial arteries
57Advances in Interventional Cardiology 2017; 13, 1 (47)
(Stryker Neurovascular, Fremont, CA, USA) – in the oth-
er patient. There were also 4 procedures that addressed 
lesions in the distal part (C4/C5; cavernous/clinoid 
segments) of the ICA, including 1 case where a self-ex-
pandable covered stent was implanted. Also, 1 patient 
developed intraprocedural embolism of the right middle 
cerebral artery, which was successfully managed using 
the Solitaire revascularization device (ev3 Endovascular, 
Plymouth, MN, USA). There were no significant complica-
tions related to the endovascular armamentarium used, 
protection systems or the stents. 
Patients presenting with arterial hypertension had 
their medications modified: calcium channel blockers, 
β-blockers and other potent antihypertensive drugs were 
not administered on the day of the endovascular proce-
dure. If such a treatment modification was not possible, 
for example in patients with low ejection fraction, during 
the procedure we administered intravenously dopamine 
or dobutamine in order to minimize stimulation of the 
baroreceptors. In a case of peri- or postprocedural hyper-
tension we administered intravenously α- or β-blockers 
instead of nitroglycerin. All the above-mentioned modi-
fications did not apply in patients managed for stenoses 
of the vertebral arteries. Periprocedural bradycardia was 
managed with the administration of atropine, and 1 such 
patient additionally required 4-hour endocavitary pac-
ing. We did not routinely perform coronary angiography 
before endovascular treatment of arteries supplying the 
brain [7].
Sonographic follow-up of the treated arteries was 
performed on the day of the procedure, and then after 
1 and 6 months. Ninety-nine percent of the patients were 
available for 30-day follow-up. Patients were advised to 
report any neurological events that occurred during this 
period. This 30-day follow-up was primarily aimed at the 
assessment of safety of these endovascular procedures. 
The primary endpoint was the proportion of patients 
who had stroke or stroke-related death. We included all 
types of strokes, both ipsi- and contralateral, as well as 
minor, major and fatal strokes. 
Neurological symptoms were categorized as follows: 
transient ischemic attack, which was defined as an acute 
neurological deficit resulting from focal temporary cere-
bral or retinal ischemia that lasted less than 24 h; stroke, 
which was defined as a  new cerebrovascular event of 
ischemic or hemorrhagic etiology resulting in cerebral 
infarction and neurological deficit. Strokes were further 
classified as: minor – with neurological deficits lasting 
less than 30 days, or lasting longer than 30 days but pre-
senting with a small deficit (National Institute of Health 
Stroke Scale up to 4 points); major – with neurological 
deficits lasting longer than 30 days, and fatal: as a stroke 
(ischemic or hemorrhagic) resulting in death. 
The secondary endpoint was the proportion of pa-
tients who had myocardial infarction (both ST elevation 
myocardial infarction (STEMI) and non-STEMI events) 
or a death that was not caused by stroke. Death of any 
non-stroke cause was taken into account. In addition to 
demographic and clinical data of the patients, we ana-
lyzed angiographic characteristics, such as presence of 
coexisting lesions in other arteries supplying the brain, 
including intracranial stenoses. Also, we assessed en-
dovascular technique used (type of protection, type of 
stent, duration of the procedure, duration of occlusion of 
an artery, etc.). 
Statistical analysis
Continuous variables were expressed as means ± 
standard deviation, categorical variables were expressed 
as percentages. Analysis of normality was performed 
with the Kolmogorov-Smirnov test. Comparison of cat-
egorical variables between the groups was performed 
using the c2 test. Comparisons of continuous variables 
between the two groups were performed using the inde-
pendent sample t-test. Multivariate, stepwise backward 
conditional logistic regression analysis was used to de-
termine independent predictors of successful interven-
tion. All significant parameters in the univariate analysis 
were selected in the multivariate model. The significance 
of the two-tailed p was set at p < 0.05. Statistical anal-
ysis was performed using the SPSS software (Statistical 
Package for the Social Sciences, version 23.0, SPSS Inc., 
Chicago, IL, USA).
Results
During 30-day follow-up there were 2 (0.5%) fatali-
ties. One patient died 30 days after the procedure due 
to intracerebral bleeding, which occurred on the 3rd day 
after stenting of the carotid artery, and the other patient, 
who presented with severe stenosis of the aortic valve 
and was planned for aortic valve replacement after ca-
rotid stenting, died because of acute decompensation 
of the left ventricle. During 30-day follow-up there were 
6 (1.5%) strokes: 2 (0.5%) major strokes and 4 (1.0%) minor 
strokes. Regarding ipsilateral strokes, there was 1 (0.2%) 
major stroke, which occurred in a patient with a history of 
stroke of the left hemisphere, occlusion of the left ICA, ste-
nosis of the brachiocephalic trunk and clinical symptoms 
of brain stem ischemia. During the procedure this patient 
developed embolization of the brain stem, which occurred 
before the distal protection system had been introduced. 
Since there were contraindications for thrombolytic thera-
py, this patient was managed conservatively.
There were also 4 (1.0%) minor contralateral and 
1 (0.2%) major contralateral stroke. The latter took place 
after hospital discharge, on the 5th postprocedural day. 
This patient had a history of cerebral stroke in the territo-
ry of the occluded right ICA, and a new stroke developed 
in the same part of the brain. In the group of asymp-
tomatic patients there were: 1 (0.5%) minor stroke and 
1 case of transient ischemia of the left hemisphere that 
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completely resolved within 6 h of fibrinolytic therapy. In 
the group of symptomatic patients there were: 3 (1.4%) 
minor strokes and 2 (0.9%) major strokes, 1 ipsilateral 
and the other contralateral. Transient ischemic attacks 
occurred in 5 (1.2%) patients, 2 such events in asymp-
tomatic patients and 3 in symptomatic ones.
Patients who developed contralateral strokes, before 
the procedure, were diagnosed with stenoses and occlu-
sions of other arteries supplying the brain. In 2 such cas-
es strokes were probably of hemodynamic mechanism 
and could have developed due to the steal phenomenon: 
an improvement of perfusion in the territory of the re-
vascularized artery and simultaneous deterioration of 
cerebral flow in the territory supplied by another, already 
compromised artery. In both these patients neurological 
symptoms resolved, respectively, after 6 and 9 days. 
There was 1 (0.2%) case of postprocedural hyperper-
fusion syndrome. This patient, who presented with bilat-
eral critical stenosis of the ICAs, developed this syndrome 
after successful revascularization of the left ICA. Conser-
vative management resulted in complete resolution of 
neurological symptoms after 5 days. After one month 
this patient underwent successful revascularization of 
the contralateral artery. Nine (2.2%) patients developed 
neurological symptoms after introduction of the protec-
tion system, which probably resulted from carotid artery 
spasm or cerebral flow impairment in a case of occlusion 
of the contralateral artery. Such intolerance occurred in 
3 patients managed with proximal protection and 6 pa-
tients managed with distal protection. Still, the intoler-
ance was of no further clinical consequence, and at 30-
day follow-up all these patients were free of neurological 
symptoms. 
There were 2 (1.0%) non-STEMI myocardial infarctions 
in asymptomatic patients. In both of them elective coro-
nary bypass grafting was planned after carotid stenting, 
and because of this complication urgent coronary angio-
plasty, with implantation of drug-eluting stents, was per-
formed, with no further significant adverse events. After 
the procedure 19 (9.6%) asymptomatic and 31 (14.7%) 
symptomatic patients developed hypotension, which re-
quired intravenous administration of dopamine, yet did 
not result in further clinical sequelae. 
Details regarding complications in asymptomatic and 
symptomatic patients are given in Table V. Of note, there 
were no statistically significant differences between 
these groups of patients. 
Logistic multivariate analysis revealed a  number of 
risk factors predisposing to postprocedural stroke and/or 
death. Some of these factors, such as bilateral stenosis 
of the ICA, applied both to asymptomatic and symptom-
atic patients. Other factors seemed to be unique for the 
particular group. Details are given in Table VI.
Discussion
There is a high divergence of published trials on en-
dovascular treatment of carotid artery stenosis in terms 
of safety and efficacy of these procedures. These results 
particularly differ between the centers with a  high ex-
pertise in carotid stenting and those centers that partic-
ipated in randomized controlled trials (doctors from the 
latter centers are usually more experienced in conduct-
Table V. Complications in asymptomatic vs. symptomatic patients
Complications during 30-day follow-up Asymptomatic patients 
(197 procedures)
Symptomatic patients 
 (211 procedures)
P-value
Ipsilateral major stroke 0 1 NS
Contralateral major stroke 0 1 NS
Ipsilateral minor stroke 0 0 NS
Contralateral minor stroke 1 3 NS
Intraprocedural embolism of intracranial arteries  
(managed endovascularly) 
0 1 NS
Transient cerebral ischemia, managed with fibrinolytic agents  1 0 NS
Transient ischemic attack 2 3 NS
Intracranial bleeding (fatal) 1 0 NS
Subarachnoid bleeding (non-fatal) 0 1 NS
Hyperperfusion syndrome 1 0 NS
Myocardial infarction, managed with percutaneous carotid angioplasty 2 0 NS
Myocardial infarction, managed conservatively 0 0 NS
All fatalities during 30-day follow-up 2 0 NS
NS – difference statistically not significant.
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Table VI. Risk factors associated with postprocedural complications (strokes and/or death) revealed by logistic 
multivariate analysis in asymptomatic vs. symptomatic patients
Asymptomatic patients (197 procedures) Symptomatic patients  (211 procedures)
Risk factor Hazard 
ratio
P-value Risk factor Hazard 
ratio
P- value
Diabetes mellitus type 2 26.27 0.001 Diabetes mellitus type 2 12.10 0.017
Stenosis localized in tortuous segment  
of the artery 
10.74 0.005 Stenosis localized in tortuous segment  
of the artery
4.91 0.027
Presence of embolic material in the filter 6.95 0.008 Presence of embolic material in the filter 5.75 0.016
Bilateral stenoses of the internal carotid 
artery
4.36 0.037 Bilateral stenoses of the internal carotid 
artery
7.41 0.006
Renal impairment 6.06 0.014 Grade 3 arterial hypertension 10.30 0.016
Advanced coronary artery disease 4.06 0.044 Cigarette smoking 5.29 0.021
Lesion requiring predilatation 4.88 0.027
Dislipidemia 4.82 0.028
ing a trial, but not necessarily regarding technical skills) 
[5–7, 9, 10]. While centers participating in the trials re-
ported 30-day complication rates at the level of 2–5% 
in asymptomatic patients, and even as high as 10.9% 
in symptomatic individuals [8–13], such rates reported 
by highly experienced centers were: 0.9–2.4% for stroke 
and/or death in all patients, 0.4–2.3% in asymptomat-
ic and 1.1–3.5% in symptomatic patients [5–7, 14]. Our 
data are similar to the latter centers: the 30-day rate of 
stroke and/or death was 2.0%, and the stroke rate was 
1.5%. The stroke rate in asymptomatic patients was 
0.5%, and in symptomatic ones 2.4%. Of note, many of 
our patients suffered from severe vascular disease: ap-
proximately 50% of patients presented with bilateral le-
sions in the carotid arteries, including 14% of them with 
occlusion of one of the ICAs, and 9% of patients had high 
grade or occlusion of the vertebral artery.
In each patient we carefully tailored the technique 
and armamentarium used, respecting anatomy of the 
arteries and location of the lesions. The proximal protec-
tion system was preferred, and even in technically diffi-
cult cases there were no complications associated with 
the use of this type of protection. In order to minimize 
the likelihood of adverse events, when using proximal 
protection, complete closure of the common carotid ar-
tery was postponed until the guidewire and stent had 
been introduced to the distal part of the system. The to-
tal rate of intolerance of proximal protection was 3.0%. 
Such a low incidence of adverse events is in line with 
the results of other researchers [8, 15]. In 2 cases we ap-
plied both distal and proximal protection. Such manage-
ment of a complex pathology has already been revealed 
to be safe [16, 17].
In addition to proper choice of the protection system, 
stents should be tailored to the lesion. Stenoses located 
in proximal parts of the common carotid artery or verte-
bral arteries, as well as those of the subclavian arteries, 
were managed using balloon-expandable stents. In the 
case of vertebral artery lesions drug-eluting stents were 
preferred. Lesions in the distal parts of the common ca-
rotid arteries and in the ICAs were managed using self-ex-
pandable stents, preferentially with a closed-cell design. 
Closed-cell stents were used in the majority of patients. If 
such a stent could not be used, we opted for an open-cell 
stent with as small as possible size of the cells. Although 
we did not observe any statistically significant differences 
between patients’ outcomes associated with the use of 
either close- or open-cell stents, other researchers have 
reported fewer complications after closed-cell devices [6, 
7, 18]. Recently, a new generation of carotid stents has 
been marketed; these stents combine small area of the 
cells with flexibility characteristic for open-cell devices. 
Perhaps, such stents, which appear to be an interesting 
alternative to currently utilized devices, will further im-
prove the results of carotid stenting [19, 20].
In 4 of our patients we addressed the lesions located 
intracranially. In all these cases the procedures were free 
of complications. In addition, in 3 patients we implant-
ed carotid stents distally, up to the C4/C5 segment of 
the ICA. Two intracranial procedures were performed to 
manage complications; there was one local intra-arterial 
fibrinolysis and one mechanical thrombectomy. In a case 
of intraprocedural cerebral embolism also other research-
ers performed mechanical recanalization, using either 
stents or balloons, and such management appeared to 
be both safe and efficient, similarly to the treatment of 
intracranial lesions of the vertebral arteries [6, 7, 13, 21]. 
A possibility to address lesions or complications located 
intracranially seems to improve the safety of endovascu-
lar procedures of extracranial arteries. 
Statistical analysis revealed that diabetes mellitus, 
tortuosity of the artery in the area of stenosis, presence 
of embolic material in the filter and bilateral stenoses 
of the ICAs were associated with an increased risk of 
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postprocedural complications in both asymptomatic 
and symptomatic patients. Two of these risk factors are 
particularly associated with a  potential technical fail-
ure: bilateral stenosis substantially limits the possibil-
ity to use proximal protection, while tortuosity of the 
artery makes the safe introduction of distal protection 
challenging. Other risk factors were different in asymp-
tomatic and symptomatic groups. Details are given in 
Table VI. Our data are similar to the already published 
research, which has identified diabetes mellitus, bilat-
eral stenoses of the carotid arteries, age of the patient 
more than 80 years and female sex as independent risk 
factors [5–7, 22–24].
Although there are some studies on carotid artery 
stenting where protection systems were not used [25], 
similarly to others [5–7, 26, 27] we opt for obligatory use of 
a protection system. After the procedures we found macro-
scopic embolic material in filters in 20 asymptomatic and 
47 symptomatic patients, and in 7 symptomatic patients 
there was quite a lot of such potentially dangerous debris. 
Also, research has demonstrated that there are fewer com-
plications if the procedures are performed by experienced 
interventionalists, and there seems to be a learning curve 
with a significant drop in the complication rate with more 
than 200 procedures performed [5–7, 28, 29].
There are several limitations of this study. Firstly, 
this is a  retrospective analysis and the patients were 
not randomized. Also, only early outcomes, with 30-day 
follow-up, were analyzed. Secondly, high heterogeneity 
of patients and technical details, including clinical sta-
tus, anatomic location and characteristics of lesions, 
and endovascular armamentarium used, makes a  reli-
able statistical analysis of data difficult. Still, analyses of 
such registers have already demonstrated that the use 
of endovascular technique tailored to the characteristics 
of stenosis, management of intracranial lesions and the 
use of novel endovascular devices can result in better 
results of these procedures and in acceptable complica-
tion rates. 
Conclusions
Our results suggest that endovascular treatment of 
extracranial arteries supplying the brain, which is tai-
lored to the type and anatomy of lesions, is a relatively 
safe procedure. Postprocedural complications are more 
common in patients presenting with several risk factors: 
diabetes mellitus, lesions localized in a tortuous segment 
of the artery, presence of embolic material in the filter 
and bilateral stenoses of the internal carotid artery. In 
addition, such adverse events were more common in as-
ymptomatic patients presenting with renal impairment 
and advanced coronary artery disease. In symptomatic 
patients these additional risk factors were grade 3 ar-
terial hypertension, dislipidemia, cigarette smoking and 
presence of lesions requiring predilatation.
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